Tatyana Storozhenko, Olga Petyunina, Alexander Berezin, Mykola Kopytsya
{"title":"巨噬细胞迁移抑制因子（MIF）：能否为心血管疾病的未来治疗铺平道路？","authors":"Tatyana Storozhenko, Olga Petyunina, Alexander Berezin, Mykola Kopytsya","doi":"10.1080/14728222.2025.2537414","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Macrophage migration inhibitory factor (MIF) is a multifunctional cytokine involved in immune regulation, inflammation, and tissue homeostasis. Elevated MIF levels contribute to the progression of various cardiovascular diseases (CVDs), making it an attractive therapeutic target. However, the pleiotropic nature and complexity of MIF context-dependent effects pose significant challenges for clinical translation, but also offer unique opportunities to develop new precision medicine-based tools.</p><p><strong>Areas covered: </strong>This review summarizes the biological functions of MIF and its homolog MIF-2 in CVD pathogenesis, along with the current landscape of therapies targeting MIF. We highlight recent preclinical findings, discuss ongoing controversies surrounding MIF's dual roles, and explore the potential of personalized approaches.</p><p><strong>Expert opinion: </strong>MIF represents a promising yet complex target in cardiovascular medicine. Future success in clinical application will depend on the development of highly selective modulators, integration of patient stratification strategies and MIF-based interventions as part of multimodal cardiovascular care.</p>","PeriodicalId":12185,"journal":{"name":"Expert Opinion on Therapeutic Targets","volume":"29 7","pages":"415-421"},"PeriodicalIF":4.4000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Macrophage migration inhibitory factor (MIF): can functional insights pave the way for future therapeutics in cardiovascular diseases?\",\"authors\":\"Tatyana Storozhenko, Olga Petyunina, Alexander Berezin, Mykola Kopytsya\",\"doi\":\"10.1080/14728222.2025.2537414\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Macrophage migration inhibitory factor (MIF) is a multifunctional cytokine involved in immune regulation, inflammation, and tissue homeostasis. Elevated MIF levels contribute to the progression of various cardiovascular diseases (CVDs), making it an attractive therapeutic target. However, the pleiotropic nature and complexity of MIF context-dependent effects pose significant challenges for clinical translation, but also offer unique opportunities to develop new precision medicine-based tools.</p><p><strong>Areas covered: </strong>This review summarizes the biological functions of MIF and its homolog MIF-2 in CVD pathogenesis, along with the current landscape of therapies targeting MIF. We highlight recent preclinical findings, discuss ongoing controversies surrounding MIF's dual roles, and explore the potential of personalized approaches.</p><p><strong>Expert opinion: </strong>MIF represents a promising yet complex target in cardiovascular medicine. Future success in clinical application will depend on the development of highly selective modulators, integration of patient stratification strategies and MIF-based interventions as part of multimodal cardiovascular care.</p>\",\"PeriodicalId\":12185,\"journal\":{\"name\":\"Expert Opinion on Therapeutic Targets\",\"volume\":\"29 7\",\"pages\":\"415-421\"},\"PeriodicalIF\":4.4000,\"publicationDate\":\"2025-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Expert Opinion on Therapeutic Targets\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/14728222.2025.2537414\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/7/27 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Opinion on Therapeutic Targets","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14728222.2025.2537414","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/27 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
Macrophage migration inhibitory factor (MIF): can functional insights pave the way for future therapeutics in cardiovascular diseases?
Introduction: Macrophage migration inhibitory factor (MIF) is a multifunctional cytokine involved in immune regulation, inflammation, and tissue homeostasis. Elevated MIF levels contribute to the progression of various cardiovascular diseases (CVDs), making it an attractive therapeutic target. However, the pleiotropic nature and complexity of MIF context-dependent effects pose significant challenges for clinical translation, but also offer unique opportunities to develop new precision medicine-based tools.
Areas covered: This review summarizes the biological functions of MIF and its homolog MIF-2 in CVD pathogenesis, along with the current landscape of therapies targeting MIF. We highlight recent preclinical findings, discuss ongoing controversies surrounding MIF's dual roles, and explore the potential of personalized approaches.
Expert opinion: MIF represents a promising yet complex target in cardiovascular medicine. Future success in clinical application will depend on the development of highly selective modulators, integration of patient stratification strategies and MIF-based interventions as part of multimodal cardiovascular care.
期刊介绍：
The journal evaluates molecules, signalling pathways, receptors and other therapeutic targets and their potential as candidates for drug development. Articles in this journal focus on the molecular level and early preclinical studies. Articles should not include clinical information including specific drugs and clinical trials.
The Editors welcome:
Reviews covering novel disease targets at the molecular level and information on early preclinical studies and their implications for future drug development.
Articles should not include clinical information including specific drugs and clinical trials.
Original research papers reporting results of target selection and validation studies and basic mechanism of action studies for investigative and marketed drugs.
The audience consists of scientists, managers and decision makers in the pharmaceutical industry, academic researchers working in the field of molecular medicine and others closely involved in R&D.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
